Department of Hematology, The Air Force Hospital From Eastern Theater of PLA, Nanjing, 210000, People's Republic of China.
Huai'an Second People's Hospital, Huai'an, Jiangsu, People's Republic of China.
Clin Exp Med. 2020 Aug;20(3):381-385. doi: 10.1007/s10238-020-00630-7. Epub 2020 May 26.
To review the efficacy and safety of glucocorticoids combined with different regimens for treating severe immune thrombocytopenia (ITP). Eighty-five severe ITP patients from 2 tertiary hospitals treated with glucocorticoids were enrolled from January 2018 to May 2019 and divided into 4 treatment groups: group A (treated with glucocorticoids), group B (glucocorticoids plus intravenous immunoglobulin (IVIg)), group C (glucocorticoids plus recombinant human thrombopoietin (rhTPO)), and group D (glucocorticoids plus IVIg and rhTPO). Statistical analysis was performed with SPSS 19.0 software. Early responses and response maintenance were assessed at 14 days and 1 month after treatment. Groups B, C and D had higher complete response (CR) and overall response (OR) rates than group A (P < 0.05). Adverse reaction incidences were not significantly different among all groups (P > 0.05). Severe ITP patients who received glucocorticoids with IVIg and rhTPO had higher CRs and ORs at the platelet level, and no significant adverse reactions were observed. Glucocorticoids combined with different regimens had different clinical efficacies for treating severe ITP.
回顾糖皮质激素联合不同方案治疗重症免疫性血小板减少症（ITP）的疗效和安全性。 2018 年 1 月至 2019 年 5 月，我们从 2 家 3 级医院共纳入 85 例接受糖皮质激素治疗的重症 ITP 患者，并将其分为 4 个治疗组：A 组（糖皮质激素组）、B 组（糖皮质激素+静脉注射免疫球蛋白（IVIg）组）、C 组（糖皮质激素+重组人血小板生成素（rhTPO）组）和 D 组（糖皮质激素+IVIg+rhTPO 组）。采用 SPSS 19.0 软件进行统计学分析。在治疗后 14 天和 1 个月评估早期反应和维持反应。B、C 和 D 组的完全缓解（CR）和总反应（OR）率均高于 A 组（P<0.05）。所有组的不良反应发生率无显著差异（P>0.05）。接受糖皮质激素联合 IVIg 和 rhTPO 的重症 ITP 患者的血小板水平 CR 和 OR 更高，且未观察到明显的不良反应。糖皮质激素联合不同方案治疗重症 ITP 的临床疗效不同。
